Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL175992 | 0.93 | CHRNA7 (0.58) | CHRNA7DRD4KCNH2DRD2SIGMAR1 | |
| SCHEMBL82888 | 0.84 | MAPT (0.47) | DRD4SIGMAR1MAPTKDM4E | |
| SCHEMBL7423220 | 0.83 | OPRD1 (0.60) | CHRNA7DRD4KCNH2DRD2SIGMAR1 | |
| SCHEMBL4553991 | 0.82 | OPRD1 (0.54) | DRD4DRD2SIGMAR1MAPTHTR1A | |
| SCHEMBL576673 | 0.78 | LMNA (0.58) | CHRNA7DRD4KCNH2DRD2SIGMAR1 | |
| SCHEMBL577708 | 0.78 | LMNA (0.58) | CHRNA7DRD4KCNH2DRD2SIGMAR1 | |
| SCHEMBL14500221 | 0.78 | LMNA (0.58) | CHRNA7DRD4KCNH2DRD2SIGMAR1 | |
| SCHEMBL15304372 | 0.77 | CHRNA7 (0.85) | CHRNA7DRD4KCNH2DRD2SIGMAR1 | |
| SCHEMBL24508006 | 0.77 | KDM4E (0.56) | CHRNA7DRD4KCNH2DRD2SIGMAR1 | |
| SCHEMBL3263264 | 0.76 | MAPT (0.43) | CHRNA7DRD4KCNH2DRD2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-9688640-B2 | Methods of treating cancer with a pyrazole derivative | ASTRAZENECA AB (SE) | 2017-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | CHRNA7 4824/4885DRD4 3701/4885KCNH2 2560/4885 |
| US-20170260143-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | CHRNA7 4792/4885DRD4 4496/4885KCNH2 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.